tradingkey.logo

Clearside Biomedical Inc <CLSD.OQ> expected to post a loss of 10 cents a share - Earnings Preview

ReutersAug 8, 2025 12:51 PM
  • Clearside Biomedical Inc CLSD.OQ CLSD.O is expected to show a rise in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025

  • The Alpharetta Georgia-based company is expected to report a 88.9% increase in revenue to $170 thousand from $90 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Clearside Biomedical Inc is for a loss of 10 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Clearside Biomedical Inc is $5.00, about 92.3% above its last closing price of $0.38

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2025

-0.11

-0.11

-0.11

Met

-1.3

Dec. 31 2025

-0.04

-0.10

-0.10

Met

-2.9

Sep. 30 2024

-0.12

-0.12

-0.10

Beat

19.5​

Jun. 30 2024

-0.13

-0.13

-0.10

Beat

25.9

​​Mar. 31 2024

-0.14

-0.14

-0.15

Missed

-9

Dec. 31 2023

-0.08

-0.09

-0.08

Beat

8.6​

Sep. 30 2023

-0.16

-0.15

-0.15

Met

3.2

Jun. 30 2023

-0.14

-0.14

-0.15

Missed

-5.9

This summary was machine generated August 8 at 12:51 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI